| 0.1586 0 (0%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.15  |
1-year : | 0.23 |
| Resists | First : | 0.12 |
Second : | 0.2 |
| Pivot price | 0.01 |
|||
| Supports | First : | 0.01 |
Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.02 |
| MA(100) : | 0.22 |
MA(250) : | 1.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.9 |
D(3) : | 8.5 |
| RSI | RSI(14): 29 |
|||
| 52-week | High : | 5.17 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLS ] has closed above bottom band by 15.1%. Bollinger Bands are 93.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Tue, 28 Mar 2023
Gelesis Reports Fourth Quarter and Full Year 2022 Results - Business Wire
Thu, 05 Jan 2023
Gelesis to Participate in the 25th Annual ICR Conference - BioSpace
Wed, 16 Nov 2022
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday By Benzinga - Investing.com UK
Mon, 14 Nov 2022
Gelesis Reports Third Quarter 2022 Results - Business Wire
Tue, 01 Nov 2022
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity ... - Business Wire
Thu, 25 Aug 2022
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 52.7 (%) |
| Held by Institutions | 29.3 (%) |
| Shares Short | 515 (K) |
| Shares Short P.Month | 511 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | -216.5 % |
| Operating Margin | -472.8 % |
| Return on Assets (ttm) | -61 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.04 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|